DOI QR코드

DOI QR Code

Frequency and Type Distribution of Human Papilloma Virus in Patients with Prostate Cancer, Kerman, Southeast of Iran

  • Atashafrooz, Fatemeh (Department of Microbiology, Kerman Branch, Islamic Azad University) ;
  • Rokhbakhsh-Zamin, Farokh (Department of Microbiology, Kerman Branch, Islamic Azad University)
  • Published : 2016.08.01

Abstract

Prostatic cancer is the second cause of cancer-related death among men worldwide. The human papilloma viruses (HPVs) are a family of sexually transmitted viruses which have may have roles in the ethiology of inflammation in prostate leading to benign prostatic hyperplasia (BPH) and prostate cancer (PCa). In this study, we evaluated the frequency of different HPV types in prostatic cancer and benign prostatic hyperplasia (BPH) in Kerman province, southeast of Iran, using real-time PCR techniques. The aim of the present research was to clarify any association with prostatic carcinogenesis. Real Time PCR showed that HPV DNA was found in 20% of 200 PCa samples, 80 percent of these with high-risk HPV types, 40% with type-16,18, 30 % type-31,33 and 10% type 54. High risk HPV DNA was detected in only 2% of BPH samples. Values for low risk types were much higher. Our study provided a support for the role of high risk HPV infection in prostatic disease in Iranian patients, and association between presence of HPV DNA and prostate carcinoma. In particular, HPV 16 and18 might have an important role in prostate cancer.

Keywords

Benign prostatic hyperplasia;prostate cancer;human papillomavirus real time PCR;Kerman

References

  1. Adami HO, Kuper H, Andersson SO, et al (2003). Prostate cancer risk and serologic evidence of human papillomavirus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev, 12, 872-5.
  2. Afshar RM, Mollaie HR, Fazlalipour M, et al (2013). Prevalence and type distribution of human papillomavirus infection using the INNo-Lipa assay, Kerman, Southeast Iran. Asian Pac J Cancer Prev, 14, 5287-91. https://doi.org/10.7314/APJCP.2013.14.9.5287
  3. Agorastos T, Lambropoulos AF, Sotiriadis A, et al (2009). Prevalence and distribution of high-risk human papillomavirus in Greece. Eur J Cancer Prev, 18, 504-9. https://doi.org/10.1097/CEJ.0b013e32832abd5e
  4. Alemany L, Saunier M, Alvarado-Cabrero I, et al (2015). Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer, 136, 98-107. https://doi.org/10.1002/ijc.28963
  5. Anastos K, Hoover DR, Burk RD, et al (2010). Risk factors for cervical precancer and cancer in HIV-infected, HPV-positive Rwandan women. PLoS One, 5, 13525. https://doi.org/10.1371/journal.pone.0013525
  6. Antonsson A, Cornford M, Perry S, et al (2014). Prevalence and risk factors for oral HPV infection in young Australians. PLoS One, 9, 91761. https://doi.org/10.1371/journal.pone.0091761
  7. Barzi A, Klein EA, Dorff TB, et al (2015). Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis.
  8. Boccalini S, Tiscione E, Bechini A, et al (2012). Sexual behavior, use of contraceptive methods and risk factors for HPV infections of students living in central Italy: implications for vaccination strategies. J Prev Med Hyg, 53, 24-9.
  9. Bosnjak Z, Peric M, Krizan IR, et al (2013). Prevalence and genotype distribution of high-risk human papillomavirus (HR HPV) in male genital samples of Osijek-Baranja County. Coll Antropol, 37, 1203-8.
  10. Brody H (2015). Prostate cancer. Nature, 528, S117. https://doi.org/10.1038/528S117a
  11. Carozzi F, De Marco L, Gillio-Tos A, et al (2014). Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence. J Clin Virol, 60, 257-63. https://doi.org/10.1016/j.jcv.2014.04.009
  12. Carroll PR, Parsons JK, Andriole G, et al (2015). Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw, 13, 1534-61. https://doi.org/10.6004/jnccn.2015.0181
  13. Chelimo C, Wouldes TA, Cameron LD, et al (2013). Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. J Infect, 66, 207-17. https://doi.org/10.1016/j.jinf.2012.10.024
  14. Damay A, Fabre J, Costes V, et al (2010). Human papillomavirus (HPV) prevalence and type distribution, and HPV-associated cytological abnormalities in anal specimens from men infected with HIV who have sex with men. J Med Virol, 82, 592-6. https://doi.org/10.1002/jmv.21732
  15. de Sanjose S, Diaz M, Castellsague X, et al (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 7, 453-9. https://doi.org/10.1016/S1473-3099(07)70158-5
  16. Denny L, Adewole I, Anorlu R, et al (2014). Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer, 134, 1389-98. https://doi.org/10.1002/ijc.28425
  17. Iftner T, Eberle S, Iftner A, et al (2010). Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol, 82, 1928-39. https://doi.org/10.1002/jmv.21910
  18. Kuczyk M, Serth J, Machtens S, et al (2000). Detection of viral HPV 16 DNA in prostate cancer and benign prostatic hyperplasia by quantitative PCR-directed analysis. Prostate Cancer Prostatic Dis, 3, 23. https://doi.org/10.1038/sj.pcan.4500448
  19. Lupi S, Bergamini M, Guidi E, et al (2014). Cross-sectional seroprevalence of antibodies against 6, 11, 16 and 18 human papillomavirus (HPV) types among teenagers and young women in Italy. Ann Ist Super Sanita, 50, 171-7.
  20. Martins AE, Lucena-Silva N, Garcia RG, et al (2014). Prevalence of human papillomavirus infection, distribution of viral types and risk factors in cervical samples from human immunodeficiency virus-positive women attending three human immunodeficiency virus-acquired immune deficiency syndrome reference centres in northeastern Brazil. Mem Inst Oswaldo Cruz, 0, 0.
  21. Michopoulou V, Derdas SP, Symvoulakis E, et al (2014). Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients. Tumour Biol, 35, 12765-73. https://doi.org/10.1007/s13277-014-2604-7
  22. Niclis C, Pou SA, Bengio RH, et al (2011). Prostate cancer mortality trends in Argentina 1986-2006: an age-periodcohort and joinpoint analysis. Cad Saude Publica, 27, 123-30. https://doi.org/10.1590/S0102-311X2011000100013
  23. Orlando G, Fasolo M, Mazza F, et al (2014). Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study. Hum Vaccin Immunother, 10, 986-94. https://doi.org/10.4161/hv.27682
  24. Pierce Campbell CM, Messina JL, Stoler MH, et al (2013). Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study. J Clin Virol, 58, 652-9. https://doi.org/10.1016/j.jcv.2013.10.011
  25. Pourmand G, Salem S, Mehrsai A, et al (2007). The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev, 8, 422-8.
  26. Printz C (2015). FDA approves Gardasil 9 for more types of HPV. Cancer, 121, 1156-7. https://doi.org/10.1002/cncr.29374
  27. Reza MA, Fahimeh G, Reza MH (2012). Evaluation of xenotropic murine leukemia virus and its R426Q polymorphism in patients with prostate cancer in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3669-73. https://doi.org/10.7314/APJCP.2012.13.8.3669
  28. Rosenblatt KA, Carter JJ, Iwasaki LM, et al (2003). Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 12, 763-8.
  29. Rotola A, Monini P, Di Luca D, et al (1992). Presence and physical state of HPV DNA in prostate and urinary-tract tissues. Int J Cancer, 52, 359-65. https://doi.org/10.1002/ijc.2910520306
  30. Sadjadi A, Nooraie M, Ghorbani A, et al (2007). The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med, 10, 481-5.
  31. Safarinejad MR (2006). Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol, 17, 1166-71. https://doi.org/10.1093/annonc/mdl087
  32. Samsonov RB, Klochkova TG, Evtushenko VI (2012). [Infection of the prostate by herpesviruses and HPV in patients with prostate cancer]. Vopr Onkol, 58, 795-9.
  33. Stephanie P, Brandel F, Caitlin K, et al (2002). Prostate Cancer, Nutrition, and Dietary Supplements (PDQ (R)): Patient Version. In 'PDQ Cancer Information Summaries', Eds Bethesda (MD), J Clin Oncol, 20, 145-6
  34. Stolten M, Ledet E, Dotiwala A, et al (2015). Alternative Digit Ratios and Their Relationship to Prostate Cancer. Clin Genitourin Cancer, 14, 149-52
  35. Vinodhini K, Shanmughapriya S, Das BC, et al (2012). Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstet, 285, 771-7. https://doi.org/10.1007/s00404-011-2155-8
  36. Walczak L, Dutkiewicz S, Marszalek A (2013). Incidence and prevalence of multiple types of genital human papillomavirus (HPV) infection in men: a study in Poland. Ginekol Pol, 84, 112-5.